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Abstract: Proton-pump inhibitors (PPIs) are commonly used after kidney transplantation and there 
is rarely an incentive to discontinue treatment. In the general population, PPI use has been 
associated with hypomagnesaemia. We aimed to investigate whether PPI use is associated with 
plasma magnesium, 24-h urinary magnesium excretion and hypomagnesaemia, in kidney 
transplant recipients (KTR). Plasma magnesium and 24-h urinary magnesium excretion were 
measured in 686 stable outpatient KTR with a functioning allograft for ≥1 year from the 
TransplantLines Food and Nutrition Biobank and Cohort-Study (NCT02811835). PPIs were used by 
389 KTR (56.6%). In multivariable linear regression analyses, PPI use was associated with lower 
plasma magnesium (β: –0.02, P = 0.02) and lower 24-h urinary magnesium excretion (β: –0.82, P < 
0.001). Moreover, PPI users had a higher risk of hypomagnesaemia (plasma magnesium <0.70 
mmol/L), compared with non-users (Odds Ratio (OR): 2.12; 95% confidence interval (CI) 1.43–3.15, 
P < 0.001). This risk tended to be highest among KTR taking high PPI dosages (>20 mg omeprazole 
Eq/day) and was independent of adjustment for potential confounders (OR: 2.46; 95% CI 1.32–4.57, 
P < 0.005). No interaction was observed between PPI use and the use of loop diuretics, thiazide 
diuretics, tacrolimus, or diabetes (Pinteraction > 0.05). These results demonstrate that PPI use is 
independently associated with lower magnesium status and hypomagnesaemia in KTR. The 
concomitant decrease in urinary magnesium excretion indicates that this likely is the consequence 
of reduced intestinal magnesium absorption. Based on these results, it might be of benefit to 
monitor magnesium status periodically in KTR on chronic PPI therapy.  
Keywords: proton-pump inhibitors; magnesium; hypomagnesaemia; kidney transplantation 
 
1. Introduction 
Proton-pump inhibitors (PPIs) are frequently used after kidney transplantation for their gastro- 
protective properties in the setting of immunosuppressive therapy, which usually includes 
glucocorticoids. Since their first introduction in the late 1980s, numerous case reports and 
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observational studies have been published that associate PPI use with unfavorable clinical outcomes, 
including an increased risk of hypomagnesaemia [1–8]. Recently, this observation has been 
strengthened by a large population based cohort study which demonstrated a two times higher risk 
of hypomagnesaemia among subjects from the general populations on chronic PPI therapy 
compared to non-users [9].  
Magnesium homeostasis depends mainly on the balance between intestinal Mg2+ uptake, 
storage and resorption from bones and urinary excretion of Mg2+ via the kidneys [10]. It is postulated 
that PPIs induce hypomagnesaemia through inhibition of pH-dependent active magnesium 
absorption via transient receptor potential melastatin (TRPM) 6 and 7 channels in the intestine 
[11,12]. Moreover, increased renal magnesium retention has been observed in magnesium depleted 
subjects using chronic PPI therapy, indicating a defect in intestinal magnesium absorption or 
increased losses into the gastrointestinal tract, rather than renal magnesium wasting [1,7,13].  
Hypomagnesaemia is very common after kidney transplantation and it is generally thought to 
be a side effect of immunosuppressive therapy, especially of calcineurin inhibitors (CNI) which are 
known to induce renal magnesium wasting [14]. It has been shown that hypomagnesaemia is not 
only present in the immediate post transplantation period, but persists in about 20% of kidney 
transplant recipients (KTR) for many years after transplantation [15,16]. Importantly, 
hypomagnesaemia has been associated with onset of post-transplant diabetes mellitus (PTDM) in 
KTR [17,18] and has also been associated with increased risk of cardiovascular morbidity [19,20] and 
mortality [21] in the general population. Whether use of PPIs contributes to hypomagnesaemia in 
KTR has not been well established. To our knowledge only one cohort study investigated the 
association between PPI use and hypomagnesaemia in 512 KTR, with negative results [22]. Reasons 
for absence of an association were unclear, but may have included a low prevalence of PPI use of 
20%, which could have led to low statistical power of the study. Thus, whether PPI use negatively 
affects magnesium status after transplantation remains to be determined. We aimed to investigate 
whether PPI use is associated with magnesium status and hypomagnesaemia in a large single center 
cohort of stable outpatient KTR, in which plasma magnesium measurements were not part of 
routine clinical care but were assessed from samples that had been stored in a biobank.  
2. Methods 
2.1. Study Design and Population  
This is a cross-sectional analysis using data from a previously described prospective cohort 
study registered at clinicaltrials.gov as ‘TransplantLines Food and Nutrition Biobank and 
Cohort-study’, NCT02811835 [23]. In summary, all adult KTR with a functioning graft beyond the 
first year after transplantation and without known or apparent systemic illnesses (i.e., malignancies 
other than cured skin cancer, opportunistic infections, overt congestive heart failure) who visited the 
outpatient clinic of the University Medical Center Groningen (UMCG) between November 2008 and 
March 2011, were asked to participate. A total of 707 out of the initially 817 invited KTR signed 
informed consent. We excluded KTR with missing biomaterial (n = 8), missing data on PPI dosage (n 
= 1), with on-demand PPI use (n = 3) or using magnesium supplements (n = 6) from statistical 
analyses, leaving 689 cases eligible for analysis. Study measurements were performed during a 
single study visit at the outpatient clinic. All study procedures were conducted in adherence with 
the Declaration of Helsinki and Declaration of Istanbul. The institutional review board of the UMCG 
approved the study protocol (METC 2008/186, approved on 17 September 2008).  
2.2. Exposure Definition 
PPI type and daily dosage were obtained from electronic patient records and are demonstrated 
in Table S1. KTR using any PPI on a daily basis during a period of at least 3 months prior to the 
study visit were defined as chronic PPI users as described previously [24]. To investigate a potential 
dose–response relationship, KTR were divided into three groups based on daily PPI dose defined in 
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omeprazole equivalents: no PPI, low PPI dose (≤20 mg omeprazole equivalents/day (Eq/day)) and 
high PPI dose (>20 mg omeprazole Eq/day) [24,25]. 
2.3. Assessement of Plasma and Urinary Magnesium 
Plasma magnesium was measured in samples containing lithium heparin, using a xylidyl blue 
method (Roche Modular analyzer, Roche Diagnostics, Mannheim, Germany). Urinary magnesium 
excretion was assessed in 24 h-urine samples and measured on a MEGA clinical chemistry analyzer 
(Merck, Darmstadt, Germany). Hypomagnesaemia was defined as plasma magnesium <0.70 
mmol/L. 
2.4. Assessment of Dietary Magnesium Intake 
Dietary magnesium intake was calculated using a validated semi quantitative food frequency 
questionnaire (FFQ) developed and updated at the Wageningen University, which was filled out at 
home [26,27]. Dietary data were converted into daily nutrient intake using the Dutch Food 
Composition Table of 2006 [28]. 
2.5. Assessment of Covariates 
Medical history was obtained from electronic patient records as described previously [23]. 
History of cardiovascular disease was classified according to the International Classification of 
Diseases, 10th revision (ICD-10) code Z86.7. Body mass index (BMI) was calculated as weight in 
kilograms divided by height in meters squared. Blood pressure was measured as described in detail 
previously [29]. Information on alcohol use and smoking behavior was obtained using a 
questionnaire. Medication use, including the use of PPIs, H2-receptor antagonists, diuretics, 
prednisolone, mycophenolate mofetil (MMF), tacrolimus, cyclosporine, and sirolimus was recorded 
at baseline. Routine immunosuppressive therapy consisted of: A combination of azathioprine and 
prednisolone from 1968 to 1989; a combination of cyclosporine and prednisolone from 1989 to 1996. 
In 1997 mycophenolate motefil was added to the standard immunosuppressive regimen and 
cyclosporine was slowly withdrawn after the first year in KTR without complications. In 2012 
cyclosporine was replaced by tacrolimus, and KTR received triple-immunosuppressive therapy with 
prednisolone, tacrolimus and mycophenolate mofetil. PPIs were routinely prescribed after kidney 
transplantation for their gastro-protective properties with concurrent use of prednisolone. Blood 
samples were collected after an 8–12 h fasting period. Serum creatinine was measured using an 
enzymatic, isotope dilution mass spectrometry-traceable assay (P-Modular automated analyzer, 
Roche Diagnostics, Mannheim, Germany). Estimated glomerular filtration rate (eGFR) was 
calculated using the serum creatinine based Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation. Serum potassium, calcium, parathyroid hormone (PTH), glucose and 
hemoglobin A1c (HbA1c), were determined using standard laboratory methods. Proteinuria was 
defined as urinary protein excretion ≥0.5 g/24 h.  
2.6. Statistical Analyses 
Statistical analyses were performed using SPSS, version 23.0 (IBM corp., Armonk, NY, USA). 
Data are presented as mean ± SD for normally distributed data, median with interquartile range 
(IQR) for skewed data and number with percentage for nominal data. Differences between PPI users 
versus PPI non-users were tested using independent sample T-tests, Mann–Whitney U-tests and 
Chi-square tests or Fishers exact tests when appropriate.  
To study the effect of PPI use on plasma magnesium linear regression analyses were performed 
with adjustment for potential confounders of magnesium status including: age, sex, BMI, eGFR, 
proteinuria, time since transplantation, alcohol use, diabetes, history of cardiovascular disease, use 
of loop diuretics, thiazide diuretics, tacrolimus, cyclosporine, MMF, and dietary magnesium intake. 
To investigate the association between PPI use and hypomagnesaemia we performed logistic 
regression analyses with adjustment for the same potential confounders used in multivariable linear 
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regression analyses. Effect modification by loop diuretics, thiazide diuretics, tacrolimus and diabetes 
was tested by inclusion of interaction terms. To investigate a potential dose–response relationship 
we performed additional analyses in which KTR were divided into three groups based on daily PPI 
dose defined in omeprazole equivalents: No PPI, low PPI dose (≤20 mg omeprazole Eq/day) and 
high PPI dose (>20mg omeprazole Eq/day) [24,25]. Tests of linear trend were conducted by assigning 
the median of daily PPI dose equivalents in subgroups treated as a continuous variable. We 
performed sensitivity analyses in which H2-receptor antagonist (H2RA) users (n = 18) were excluded 
to assess the robustness of the association between PPI use and hypomagnesaemia. Lastly, we 
investigated which KTR are at increased risk of developing hypomagnesaemia. A two-sided P-value 
< 0.05 was considered statistically significant in all analyses.  
3. Results 
3.1. Baseline Characteristics  
Baseline characteristics are shown in Table 1. PPIs were used by a small majority of 389 (56.5%) 
KTR and omeprazole was the most often prescribed PPI (n = 340). Other PPIs used were 
esomeprazole (n = 30), pantoprazole (n = 16), and rabeprazole (n = 3). KTR who used PPIs were older 
than KTR who did not use PPIs, had a higher BMI and had shorter time between transplantation and 
baseline measurements. Diabetes was significantly more prevalent in PPI users compared with 
non-users (28.3% vs. 18.3%, P < 0.002). Plasma magnesium and 24-h urinary magnesium excretion 
were significantly lower in PPI users and 102 (26.2%) PPI users had hypomagnesaemia compared 
with 43 (14.3%) non-users (P < 0.001). Dietary magnesium intake was not significantly different 
between PPI users and non-users. Loop diuretics, cyclosporine and MMF, were more often used by 
PPI users compared with non-users. Triple immunosuppressive therapy consisting of MMF, 
cyclosporine and prednisolone, was more common in PPI users compared with non-users. Duo 
therapy consisting of MMF-prednisolone, MMF-cyclosporine, and cyclosporine-prednisolone was 
more common in PPI users compared with non-users. 
Table 1. Baseline characteristics of 689 kidney transplant recipients. 
Characteristics Total Population Non-PPI Users PPI Users P 
Number of subjects, n (%) 689 (100) 300 (43.5) 389 (56.5) n/a 
Demographics     
Age, year 53 ± 13 51 ± 13 54 ± 12 0.001 
Men, n (%) 395 (57.3) 177 (59.0) 218 (56.0) 0.4 
BMI, kg/m2 26.6 ± 4.8 25.9 ± 4.6 27.1 ± 4.8 0.002 
Diabetes Mellitus, n (%) 165 (23.9) 55 (18.3) 110 (28.3) 0.002 
History of CV disease, n (%) 274 (39.8) 92 (30.7) 182 (46.8) <0.001 
Time since transplantation, year 5.5 (1.9–12.1) 9.6 (4.1–15.0) 4.2 (1.1–8.7) <0.001 
Lifestyle parameters     
Current smoker, n (%) 84 (13.0) 35 (12.4) 49 (13.6) 0.7 
Alcohol consumer, n (%) 436 (70.3) 198 (72.8) 238 (68.4) 0.2 
Magnesium intake, mg/day 329.9 ± 88.7 333.0 ± 89.2 327.6 ± 88.4 0.5 
Renal function parameters     
eGFR, mL/min/1.73 m2  52.3 ± 20.2 55.1 ± 19.9 50.2 ± 20.1 0.002 
Serum creatinine, µmol/L 124 (100–160) 119 (98–152) 128 (101–168) 0.03 
Proteinuria (≥0.5 g/24 h), n (%) 157 (22.9) 71 (23.7) 86 (22.2) 0.7 
Laboratory parameters     
Hypomagnesaemia, n (%) 145 (21.0) 43 (14.3) 102 (26.2) <0.001 
Plasma magnesium, mmol/L 0.77 ± 0.11 0.79 ± 0.09 0.76 ± 0.11 <0.001 
24-h urinary magnesium excretion, 
mmol/24 h 
3.3 (2.3–3.3) 3.8 (2.8–4.8) 3.1 (2.0–3.9) <0.001 
Serum potassium, mmol/L 3.98 ± 0.46 3.97 ± 0.47 3.99 ± 0.46 0.6 
Serum calcium, mmol/L 2.40 ± 0.15 2.40 ± 0.15 2.40 ± 0.15 0.8 
PTH, pmol/L 9.0 (6.0–14.8) 8.7 (6.0–13.6) 9.2 (5.9–16.3) 0.2 
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Glucose, mmol/L 5.3 (4.8–6) 5.2 (4.7–5.8) 5.3 (4.8–6.2) 0.01 
HbA1c, mmol/mol 40 (37–44) 39 (36–42) 41 (38–45) <0.001 
Medication use     
Mycophenolate mofetil, n (%) 452 (65.6) 178 (59.3) 274 (70.4) 0.002 
Tacrolimus, n (%) 124 (18.0) 49 (16.3) 75 (19.3) 0.3 
Cyclosporine, n (%) 272 (39.5) 97 (32.3) 175 (45.0) 0.001 
Sirolimus, n (%) 13 (2.0) 8 (2.8) 5 (1.4) 0.3 
Prednisolone, n (%) 682 (99.0) 298 (99.3) 384 (98.7) 0.7 
Loop diuretics, n (%) 160 (23.2) 41 (13.7) 119 (30.6) <0.001 
Thiazide diuretics, n (%) 120 (17.4) 53 (17.7) 67 (17.4) 0.9 
H2-receptor antagonists, n (%) 18 (2.6) 17 (5.7) 1 (0.3) <0.001 
Combination therapy     
MMF + Tac + pred, n (%) 78 (11.3) 32 (10.7) 46 (11.8) 0.6 
MMF + Cyclo + pred, n (%) 175 (25.4) 51 (17.0) 124 (31.9) <0.001 
MMF + Tac, n (%) 81 (11.8) 33 (11.0) 48 (12.3) 0.6 
MMF + Pred, n (%) 447 (64.9) 176 (58.7) 271 (69.7) 0.003 
MMF + Cyclo, n (%) 177 (25.7) 52 (17.3) 125 (32.1) <0.001 
Cyclo + Pred, n (%) 269 (39.0) 96 (32.0) 173 (44.5) 0.001 
Tac + Pred, n (%) 120 (17.4) 48 (16.0) 72 (18.5) 0.4 
Data are presented as mean ± SD, median with interquartile ranges (IQR) or number with 
percentages (%). Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; 
HbA1c, hemoglobin A1c; PTH, Parathyroid hormone; MMF, mycophenolate mofetil; Tac, tacrolimus; 
Pred, prednisolone. 
3.2 Association of PPI Use with Plasma Magnesium and 24-h urinary Magnesium Excretion 
PPI use was significantly associated with lower plasma magnesium (β = –0.03; 95% CI −0.04; 
−0.01 mmol/L, P = 0.001) and lower urinary magnesium excretion (β = −0.86; 95% CI −1.10; −0.06 
mmol/24 h, P < 0.001) as compared to non-users, Table 2. After adjustment for potential confounders, 
PPI use remained significantly associated with lower plasma magnesium levels (β = −0.02, 95% CI 
−0.04; −0.003, P = 0.02) and 24-h urinary magnesium excretion (β = −0.82, 95% CI −1.07; −0.57, P < 
0.001). 
Table 2. Association of proton-pump inhibitor (PPI) use with plasma magnesium and 24-h urinary 
magnesium excretion in 689 kidney transplant recipients. 
 
Plasma Magnesium,  
mmol/L 
Urinary Magnesium Excretion, 
mmol/24 h 
β 95% CI P β 95% CI  P 
Crude −0.03 −0.04; −0.01 0.001 −0.86 −1.10; −0.06 <0.001 
Multivariable model −0.02 −0.04; −0.003 0.02 −0.82 −1.07; −0.57 <0.001 
Multivariable analyses were adjusted for age, sex, BMI, eGFR, proteinuria, time since 
transplantation, alcohol use, diabetes, history of CV disease, loop diuretics, thiazide diuretics, 
tacrolimus use, cyclosporine use, MMF use and dietary magnesium intake. Abbreviations: CI, 
confidence interval. 
3.3. Association of PPI Use with Hypomagnesaemia 
In crude logistic regression analysis, PPI use was associated with a more than two times higher 
risk of hypomagnesaemia compared with no use (OR: 2.12; 95% CI 1.43–3.15, P < 0.001), as shown in 
Table 3. The association remained independent of adjustment for potential confounders including 
age, sex, eGFR, proteinuria, time since transplantation, alcohol use, diabetes, history of 
cardiovascular disease, medication use (loop diuretics, thiazide diuretics, tacrolimus, cyclosporine 
and MMF) and dietary magnesium intake (OR: 2.00; 95% CI 1.21–3.31, P = 0.007). No significant 
interaction was observed between PPI use and the use of loop diuretics, thiazide diuretics, 
tacrolimus, or diabetes for the association with hypomagnesaemia (Pinteraction = 0.2, Pinteraction = 0.7, 
Pinteraction = 0.7, Pinteraction = 0.9, respectively). 
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Table 3. Logistic regression analyses investigating the association of PPI use with hypomagnesaemia 
in 689 kidney transplant recipients. 
 Hypomagnesaemia 
N = 689 Odds Ratio 95% CI P 
Crude 2.12 1.43–3.15 <0.001 
Multivariable model 2.00 1.21–3.31 0.007 
Multivariable analyses were adjusted for age, sex, BMI, eGFR, proteinuria, time since 
transplantation, alcohol use, diabetes, history of CV disease, loop diuretics, thiazide diuretics, 
tacrolimus use, cyclosporine use, MMF use and dietary magnesium intake. Abbreviations: CI, 
confidence interval. 
3.4 Dose–Response Analyses 
Based on daily dose equivalents of omeprazole, 251 KTR received a low PPI dose (≤20 mg 
omeprazole Eq/day) and 138 KTR received a high PPI dose (>20 mg omeprazole Eq/day). As shown 
in Table 4 and Figure 1, risk of hypomagnesaemia tended to be highest among KTR taking a high 
PPI dose (OR: 2.53; 95% CI 1.55–4.11, P < 0.001). The association remained materially unchanged 
after multivariable adjustment (OR: 2.46; 95% CI 1.32–4.57, P < 0.005), Table 4. Moreover, a 
significant trend between PPI dose and risk of hypomagnesaemia was observed (Ptrend = 0.004). 
Table 4. Subgroup analyses of the association of PPI use with hypomagnesaemia in 689 kidney 
transplant recipients. 
 Categories of PPI Use 
 No PPI Low PPI dose  High PPI dose  
Number of subjects  300 251 138  
 
Odds ratio (95% 
CI) 
P 
Odds ratio (95% 
CI) 
P 
Odds ratio (95% 
CI) 
P p-trend 
Hypomagnesaemia        
Crude 1.00 (reference) n/a 1.92 (1.25–2.96) 0.003 2.53 (1.55–4.11) <0.001 <0.001 
Multivariable model 1.00 (reference) n/a 1.79 (1.04–3.08) 0.04 2.46 (1.32–4.57) 0.005 0.004 
Multivariable analyses were adjusted for age, sex, BMI, eGFR, proteinuria, time since 
transplantation, alcohol use, diabetes, history of CV disease, loop diuretics, thiazide diuretics, 
tacrolimus use, cyclosporine use, MMF use, dietary magnesium intake. Low PPI dose (≤20 mg 
omeprazole Eq/day), High PPI dose (>20mg omeprazole Eq/day). Abbreviations: CI, confidence 
interval. 
 
Figure 1. Crude association between PPI use and risk of hypomagnesaemia stratified by subgroups 
of PPI use. No PPI, Low PPI dose (≤20 mg omeprazole Eq/day), High PPI dose (>20 mg omeprazole 
Eq/day). Presented are odds ratio’s with 95% confidence intervals. *P = 0.004; **P < 0.001; Ptrend < 0.001. 
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3.5 Sensitivity Analyses for Risk of Hypomagnesaemia 
To account for the use of other important gastric acid reducing medication, we performed 
sensitivity analyses in which H2RA users (N = 18) were excluded form statistical analyses (Table S2). 
The association between PPI use and hypomagnesaemia remained materially unchanged when 
H2RA users were excluded (OR: 2.17, 95% CI 1.29–3.67, P = 0.004). We also performed analyses to 
investigate which KTR are at increased risk of developing hypomagnesaemia. These analyses are 
presented in Table S3. We found that patients with a history of cardiovascular disease, patients at 
shorter time after transplantation, not consuming alcohol, PPI users, thiazide diuretic users and 
patients using tacrolimus based immunosuppressive regimens were at increased risk of developing 
hypomagnesaemia. Moreover, KTR with hypomagnesaemia had higher fasting glucose levels, 
HbA1c and lower serum calcium levels compared with KTR without hypomagnesaemia.  
4. Discussion 
The present study is to our knowledge the largest cohort study to date exploring the association 
between PPI use and hypomagnesaemia in a cohort of KTR. Our results demonstrate a higher risk of 
hypomagnesaemia among KTR using PPIs, with subsequently lower plasma magnesium levels in 
combination with lower renal magnesium excretion. The association between PPI use and risk of 
hypomagnesaemia remained significant after adjustment for important potential confounders and 
tended to be highest among KTR taking high PPI dosages. 
Our results confirm previous case-series and cohort studies investigating the association 
between PPI use and increased risk of hypomagnesaemia [1,2,7,9]. In a large cohort study (N = 9818) 
among subjects from the general population, it was shown that PPI users had significantly lower 
serum magnesium levels and had a two times higher risk of hypomagnesaemia compared with 
non-users [9]. Our results are in line with observations from this large cohort study and show a 
similar increased risk of hypomagnesaemia (OR 2.12). 
So far, only one other study by van Ende et al. investigating the association between PPI use 
and magnesium status in KTR has been published [22]. Contrary to our findings, van Ende et al. 
found no association between PPI use and serum magnesium levels. Reasons for the lower 
proportion of PPI users in the study by van Ende et al. are unclear, though underreporting may have 
played a role, given that it was not specified how data regarding PPI use was obtained. It was also 
unclear whether the data of van Ende et al. were derived from routine outpatient assessment of 
plasma magnesium concentrations, which may have provided an incentive for stopping PPI use in 
KTR with low magnesium concentrations. This could have biased their results and could possibly 
also explain the large difference in PPI use between our study and their study, because in our center 
no plasma magnesium data were available at the time of the study. It was furthermore unclear 
whether it concerned on-demand or chronic PPI use. Furthermore, data regarding PPI dose, type 
and magnesium supplementation were not reported, which may have influenced the outcome. 
In a recently published meta-analysis, a similar risk of hypomagnesaemia among KTR was 
demonstrated (pooled OR = 1.56, 95% CI 1.19–2.05) [30]. This meta-analysis by Boonpheng et al. was 
based on one published paper and seven abstracts presented at medical conferences. Our study adds 
that it investigated a dose–response relationship, and provides data on dietary magnesium intake 
and 24-h urinary magnesium excretion.  
In the present study, both plasma magnesium and 24-h urinary magnesium excretion were 
lower in PPI users, suggesting that PPI induced hypomagnesaemia is caused by impaired 
gastrointestinal absorption rather than renal magnesium wasting. In general, hypomagnesaemia can 
be the consequence of either a decreased intestinal uptake, a decrease in dietary magnesium intake 
or an increase in renal magnesium excretion. It is postulated that PPIs inhibit the active magnesium 
absorption via the TRPM 6 and 7 channels in the intestine [11,12]. In KTR other contributing factors 
than PPI use may add to the risk of hypomagnesaemia. For example, decreased intestinal 
magnesium absorption can also be the consequence of chronic post-transplant diarrhea, which is 
highly prevalent and often complicated by hypomagnesaemia [10,31]. Data regarding symptoms of 
severe diarrhea were unfortunately unavailable in this study, therefore we could not correct for this 
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potential confounder. Likewise, hypomagnesaemia can be the result of insufficient intake of foods 
rich in magnesium. In our study, mean dietary magnesium intake was 329.9 ± 88.7 mg/day, which 
was slightly lower than the mean habitual intake of magnesium among the general Dutch 
population, as reported in the Dutch National Food Consumption Survey 2007–2010 [32]. A low 
dietary magnesium intake can also be a reflection of an overall poor diet. Nonetheless, when we 
adjusted for dietary magnesium intake in our logistic regression analyses, the relationship between 
PPI use and risk of hypomagnesaemia remained materially unchanged, indicating that the observed 
risk associated with PPI use was not confounded by dietary magnesium intake.  
The main strength of this study is measurement of three important pillars of magnesium status: 
plasma magnesium, 24-h urinary magnesium excretion and dietary magnesium intake. Because of 
this, we were able to confirm that PPI use does not lead to increased renal magnesium wasting but 
very likely impairs intestinal magnesium absorption. Furthermore, we only included KTR who were 
using PPIs for at least 3 months before blood sampling. It is previously noted that hypomagnesaemia 
occurs mainly in patients on prolonged PPI therapy suggesting that it takes time before magnesium 
stores are meaningfully depleted [6,7,33]. Moreover, we excluded KTR using magnesium 
supplements and adjusted for potential confounders, including CNI use, which did not alter the 
association.  
A limitation of our study is its cross-sectional design. Therefore, a causal relationship between 
PPI use and hypomagnesaemia remains to be determined and changes over time in magnesium 
status parameters were unknown. Furthermore, no information regarding compliance to PPI 
treatment was available, which may have led to underestimation of effect sizes. PPI users had a 
shorter time between transplantation and baseline measurements. However, adjustment for time 
since transplantation did not alter the association between PPI use and hypomagnesaemia. Lastly, 
the possibility of residual confounding or bias by indication remains, which may have led to 
overestimation of the role of PPIs since on average PPI users were less healthy than non-users. A 
strength of the current study is, that no routine outpatient monitoring of plasma magnesium was 
performed and that we measured plasma and urine magnesium in samples that had been stored in a 
biobank, which reduces the change of selection bias in our cohort.  
Our findings may be of clinical importance. KTR with low magnesium levels seem to develop 
post-transplant diabetes mellitus (PTDM) more frequently [17]. In this study we also found that KTR 
with hypomagnesaemia had higher fasting glucose levels and HbA1c. Next to that, a higher degree 
of arterial stiffness, as assessed by a carotid-femoral pulse wave velocity (PWV) measurement, has 
been found in KTR with low magnesium levels [34]. This same PWV measurement was found to be 
an independent predictor of cardiovascular events in KTR [35]. Moreover, hypomagnesaemia has 
been associated with cardiovascular morbidity [19,20] and mortality [21] in the general population. 
However, whether this association is also present in KTR is currently unknown. Another clinical 
significance lies in the association with lower calcium levels, which potentially points to an increased 
risk of developing osteoporosis. Long-term PPI use has indeed been associated with decreased bone 
mineral density and increased risk of fractures [36]. Because many patients use PPIs without 
evidence based indication [37–39], we believe that reevaluation of treatment indication in KTR on 
chronic PPI therapy might be of benefit. In situations in which PPIs are clinically needed, it would be 
judicious to assess and follow-up magnesium levels periodically during treatment, as recommended 
by the US Food and Drug administration and stated in the summary of product characteristics of all 
PPIs.  
5. Conclusions 
This study demonstrates that PPI use is associated with lower magnesium status and 
hypomagnesaemia in KTR. Moreover, risk of hypomagnesaemia was higher among KTR taking a 
high PPI dosage. Healthcare professionals should be aware of this additional risk and should 
consider regular monitoring of magnesium levels, especially in this patient population at high risk of 
hypomagnesaemia.  
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